INmune Bio publishes Phase 2 Alzheimer's trial results in peer-reviewed journal

May 15, 2026 8:00 AM

INmune Bio Inc. (NASDAQ: INMB) announced that results from its Phase 2 MINDFuL trial in Alzheimer's disease have been published ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found